Posted on Sep 16 2019 11:32 AM

"Breast Cancer Therapeutics Market report covers the detailed information of Breast Cancer Therapeutics Fortune Business Insights predicts the value in the upcoming year forecast till 2025"

The Global Breast Cancer Therapeutics Market, which stood at US$ 17,868.8 Mn in 2018, will reach [US$ 38,573.5 Mn] by the end of 2026. If these figures prove true, the global breast cancer therapeutics market will rise at a CAGR of 10.2% between 2018 and 2026.

some breast cancer drugs may have serious side effects, and this may act as a hindrance to the market. Besides this, countries that lack of awareness may restrict expansion of the market. Also, social taboos prevalent in these countries may act as major deterrents to growth.

Browse Complete Report Details @ https://www.fortunebusinessinsights.com/industry-reports/breast-cancer-therapeutics-market-100163

Some of the Main Key Players Covered in the Breast Cancer Therapeutics Market Report

  • Genentech (F. Hoffmann-La Roche Ltd)
  • Eli Lilly and Company
  • Celgene Corporation
  • AstraZeneca
  • Pfizer Inc.
  • Sanofi
  • Eisai Co. Ltd.
  • Kyowa Kirin
  • Bristol Myers Squibb
  • Mayne Pharma Group Limited
  • Valeant Pharmaceuticals

North America to Remain Dominant on Account of Presence of Skilled Professionals

The increasing number of breast cancer cases all over the world is anticipated to boost the global breast cancer therapeutics market at promising rates, finds Fortune Business Insights in a new study. The study is titled, “Breast Cancer Therapeutics Market: Global Market Analysis, Insights, and Forecasts”.

Sample PDF Brochure @ https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/breast-cancer-therapeutics-market-100163

The breast cancer therapeutics market in North America is currently leading the global landscape, supported by the presence of well-established healthcare infrastructure and rising uptake of advanced facilities in the region. In 2018, North America generated a revenue of US$ 8,033.8 Mn because of the increasing prevalence of breast cancer in the region.

In addition to this, the region boasts the presence of several leading market players and skilled professionals. Besides this, governments of developed nations such as Canada and the U.S. are providing health insurance for cancer diagnostics. Spurred by these factors the breast cancer therapeutics market is likely to flourish in North America to emerge dominant.

Key Segmentation from Breast Cancer Therapeutics Market 

By Therapy

  • Targeted Therapy
  • Abemaciclib
  • Ado-Trastuzumab Emtansine
  • Everolimus
  • Trastuzumab
  • Ribociclib
  • Palbociclib
  • Pertuzumab
  • Olaparib
  • Others
  • Hormonal Therapy
  • Selective Estrogen Receptor Modulators (SERMs)
  • Aromatase Inhibitors
  • Estrogen Receptor Downregulators (ERDs)
  • Chemotherapy

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Cancer Type

  • Hormone Receptor
  • HER2+

By Geography

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Looming Patent Expiries Fuels Demand for Generic Drugs

According to the World Health Organization, in 2018, an approximate of 627,000 women, which is tantamount to 15% of all cancer deaths worldwide, succumbed to breast cancer. The rising incidence of breast cancer is one of the chief drivers of the global breast cancer therapeutics market .

The global breast cancer therapeutics market is likely to witness the prevalence of high competition. According to the report, Genentech, Inc. (F. Hoffmann-La Roche Ltd) held the dominant share in the market in 2018. Its diverse product portfolio backs growth of the company in a targeted and chemotherapy segment.

With the expiry of most patent drugs in the market, there is an increased demand for their generic counterparts. Such factors are propelling vendors to invest more in research and development and develop generic drugs for breast cancer treatment. The introduction of combination drug therapy is anticipated to create better growth opportunities for the market.

Some of the players operating in the global breast cancer therapeutics market are Puma Biotechnology, Inc., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc., Eli Lilly and Company, Novartis International AG, AstraZeneca plc, F. Hoffmann-La Roche Ltd., Sanofi S.A., GlaxoSmithKline plc, and Pfizer, Inc.

Major Table of Content for Breast Cancer Therapeutics Market

1. Introduction

1.1. Research Scope

1.2. Market Segmentation

1.3. Research Methodology

1.4. Definitions andAssumptions

2. Executive Summary

3. Market Dynamics

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities

4. Key Insights

4.1 Prevalence of BreastCancer Therapeutics by Key Countries

4.2 Regulatory Scenario byKey Regions

4.3 Key IndustryDevelopments

4.4 Overview of CurrentAdvances in R&D for Breast Cancer Therapeutics

More Trending Topics from Fortune Business Insights:

Diabetes Drugs Market to Reach US$ 78,261.7 Mn by 2026, Deriving Growth from Increasing Drug Approvals, says Fortune Business Insights

Dental Implants Market to Value US$ 5725.7 Mn at CAGR of 5.1% by 2026 | Exclusive Report by Fortune Business Insights

Implantable Cardioverter Defibrillator Market to reach US$ 8,343.4 Mn by 2026, Medtronic Leads the Market with Increasing Customer Reach, says Fortune Business Insights